ELDORANDO - Pembrolizumab compared with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115)

Klinghammer K, Graeven U, Ivanyi P, Dietz A, Hahn D, Hackenberg S, Kasper S, Fietkau R, Moulin JC, Pink D, Schaaf M, Grunwald (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

City/Town: BASEL

Pages Range: 56-57

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Rainer Fietkau Lehrstuhl für Strahlentherapie

Involved external institutions

HELIOS Kliniken DE Germany (DE) Kliniken Maria Hilf GmbH DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) Krankenhaus Nordwest DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Klinikum Stuttgart DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Ortenau Klinikum DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Universitätsklinikum Leipzig DE Germany (DE)

How to cite

APA:

Klinghammer, K., Graeven, U., Ivanyi, P., Dietz, A., Hahn, D., Hackenberg, S.,... Grunwald, . (2021). ELDORANDO - Pembrolizumab compared with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115). In ONCOLOGY RESEARCH AND TREATMENT (pp. 56-57). BASEL: KARGER.

MLA:

Klinghammer, K., et al. "ELDORANDO - Pembrolizumab compared with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2021. 56-57.

BibTeX: Download